Condition: Urothelial Carcinoma Bladder · Triple Negative Breast Cancer (TNBC) · Hormone Receptor Positive Breast Adenocarcinoma · Sponsor: Aktis Oncology, Inc.
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
This description comes directly from the study's public registry record.
Janet Horton, MD · 978-208-3986 · AKY-1189-01inquiries@aktisoncology.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Irvine, California, United States | Recruiting |
| Biogenix Molecular, LLC | Miami, Florida, United States | Recruiting |
| Advent Health Medical Group Radiation Oncology at Central Florida | Orlando, Florida, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kansas | Westwood, Kansas, United States | Recruiting |
| United Theranostics | Glen Burnie, Maryland, United States | Recruiting |
| BAMF Health | Grand Rapids, Michigan, United States | Recruiting |
| Icahn School of Medicine at Mt. Sinai | New York, New York, United States | Recruiting |
| UPMC | Pittsburgh, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07020117